Patents by Inventor Pascal Chaux

Pascal Chaux has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MAGE-A3 peptides presented by HLA class II molecules
    Publication number: 20030049723
    Abstract: The invention describes HLA class II binding peptides encoded by the MAGE-A3 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4+ T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of the MAGE-A3 gene.
    Type: Application
    Filed: May 18, 2001
    Publication date: March 13, 2003
    Inventors: Yi Zhang, Pascal Chaux, Thierry Boon-Falleur, Pierre van der Bruggen
  • Tumor antigens and CTL clones isolated by a novel procedure
    Patent number: 6531451
    Abstract: The present invention relates to isolation of cytotoxic T lymphocyte (CTL) clones. In particular, the present invention relates to isolated CTL clones that are specific for MAGE-1 and MAGE-4, respectively. The CTL clones of the present invention have been isolated by successive steps of stimulation and testing of lymphocytes with antigen presenting cells which present antigens derived from different expression systems, e.g., from recombinant Yersinia, recombinant Salmonella, or recombinant viruses. The present invention further relates to the MAGE-1 and MAGE-4 antigenic peptides as well as the peptide/HLA complexes which are recognized by the isolated CTL clones.
    Type: Grant
    Filed: April 9, 1999
    Date of Patent: March 11, 2003
    Assignees: Ludwig Institute for Cancer Research, Universite Catholique de Louvain
    Inventors: Pascal Chaux, Rosalie Luiten, Nathalie Demotte, Marie-Therese Duffour, Christophe Lurquin, Catia Traversari, Vincent Stroobant, Guy Cornelis, Thiery Boon-Falleur, Pierre van der Bruggen
  • MAGE-3 peptides presented by HLA class II molecules
    Patent number: 6426217
    Abstract: The invention describes HLA class II binding peptides encoded by the MAGE-3 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4+ T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of the MAGE-3 gene.
    Type: Grant
    Filed: October 27, 2000
    Date of Patent: July 30, 2002
    Assignees: Ludwig Institute for Cancer Research, Vrije Universiteit Brussel
    Inventors: Pascal Chaux, Vincent Stroobant, Thierry Boon-Falleur, Pierre van der Bruggen, Kris Thielemans, Jurgen Kurthals
  • MAGE-3 peptides presented by HLA class II molecules
    Patent number: 6369211
    Abstract: The invention describes the HLA class II binding peptides encoded by the MAGE-3 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4+ T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of the MAGE-3 gene.
    Type: Grant
    Filed: July 7, 1999
    Date of Patent: April 9, 2002
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Pascal Chaux, Vincent Stroobant, Thierry Boon-Falleur, Pierre van der Bruggen
  • Mage-3 peptides presented by HLA class II molecules
    Patent number: 6291430
    Abstract: The invention describes HLA class II binding peptides encoded by the MAGE-3 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4+ T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of the MAGE-3 gene.
    Type: Grant
    Filed: October 5, 1998
    Date of Patent: September 18, 2001
    Assignees: Ludwig Institute for Cancer Research, Vrije Universiteit Brussel
    Inventors: Pascal Chaux, Vincent Stroobant, Thierry Boon-Falleur, Pierre van der Bruggen, Kris Thielemans, Jurgen Kurthals
  • Mage-3 peptides presented by HLA class II molecules
    Patent number: 5965535
    Abstract: The invention describes the HLA class II binding peptides encoded by the MAGE-3 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4.sup.+ T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of the MAGE-3 gene.
    Type: Grant
    Filed: September 12, 1997
    Date of Patent: October 12, 1999
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Pascal Chaux, Vincent Stroobant, Thierry Boon-Falleur, Pierre van der Bruggen